Skip to main content
WDIWF
Sign inSign up
AP

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals develops RNAi gene-silencing medicines targeting the genetic causes of disease, with programs in TTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria.

1 job